ROIVANT SCIENCES LTD. Investment Income, Interest
ROIVANT SCIENCES LTD. (ROIV) reported Investment Income, Interest of $36.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- ROIVANT SCIENCES LTD. investment income, interest for the quarter ending 2026-06-30 was $36.92M, a 23.59% decline year-over-year.
- ROIVANT SCIENCES LTD. investment income, interest for the quarter ending 2026-03-31 was $41.18M, a 24.61% decline year-over-year.
- ROIVANT SCIENCES LTD. investment income, interest for the quarter ending 2025-12-31 was $43.27M, a 30.05% decline year-over-year.
- ROIVANT SCIENCES LTD. investment income, interest for the quarter ending 2025-09-30 was $45.34M, a 35.02% decline year-over-year.
- ROIVANT SCIENCES LTD. investment income, interest for fiscal 2026 was $178.11M, a 31.07% decline from fiscal 2025.
- ROIVANT SCIENCES LTD. investment income, interest for fiscal 2025 was $258.38M, a 76.46% increase from fiscal 2024.
- ROIVANT SCIENCES LTD. investment income, interest for fiscal 2024 was $146.43M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.92M 10-Q · filed 2026-08-06 | $78.10M derived: sum of 2 quarters · filed 2026-08-06 | $121.37M derived: sum of 3 quarters · filed 2026-08-06 | $166.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $41.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $84.45M derived: sum of 2 quarters · filed 2026-05-20 | $129.79M derived: sum of 3 quarters · filed 2026-05-20 | $178.11M 10-K · filed 2026-05-20 |
| 2025-12-31 | $43.27M 10-Q · filed 2026-02-06 | $88.61M derived: sum of 2 quarters · filed 2026-02-06 | $136.93M 10-Q · filed 2026-02-06 | $191.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-09-30 | $45.34M 10-Q · filed 2025-11-10 | $93.66M 10-Q · filed 2025-11-10 | $148.29M derived: sum of 3 quarters · filed 2026-08-06 | $210.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $48.32M 10-Q · filed 2026-08-06 | $102.95M derived: sum of 2 quarters · filed 2026-08-06 | $164.80M derived: sum of 3 quarters · filed 2026-08-06 | $234.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $54.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-20 | $116.47M derived: sum of 2 quarters · filed 2026-05-20 | $186.25M derived: sum of 3 quarters · filed 2026-05-20 | $258.38M 10-K · filed 2026-05-20 |
| 2024-12-31 | $61.85M 10-Q · filed 2026-02-06 | $131.62M derived: sum of 2 quarters · filed 2026-02-06 | $203.75M 10-Q · filed 2026-02-06 | |
| 2024-09-30 | $69.77M 10-Q · filed 2025-11-10 | $141.90M 10-Q · filed 2025-11-10 | ||
| 2024-03-31 | $146.43M 10-K · filed 2026-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |